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All individuals previously infected with Epstein-Barr virus (EBV) harbor life-long
a population of virus-infected B cells whose number appears to be controlled by
EBVspecific, HLA-restricted (class I andclass II) CTLs(CD4 andCD8) that recog-
nize a functionally defined lymphocyte-determined membrane antigen, LYDMA
(1, 2) . There are two recognized types of EBV (A and B) that show sequence diver-
gence within the reading frames encoding EBV nuclear antigens (EBNAs) 2, 3, 4,
and 6 (3, 4) and differences in the molecular weight of these proteins (4, 5) .
Ourgeneralapproach to identifyingCTLepitopes has been to isolate EBVspecific
T cell clones that recognize autologous A-type transformant but fail to lyse the cor-
responding B-type transformant (6) . The present report defines the first target epi-
tope recognized by EBVspecific CTLs . Our approach to identifying this epitope
has been to screen selected peptide sequences from theEBNA proteins using specific
CTLs and the autologous B-type transformant.
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CellLines.
￿
EBVtransformed cell lines (LCLs) were established either spontaneously (i .e .,
by transformation with endogenous virus) or by the addition ofexogenous virus (7) . A spon-
taneous LCL from the EBV seropositive donor LC was established using cyclosporin A (8) .
The type of endogenous virus (A or B) in the spontaneous cell lines was determined using
Southern analysis (6) and was used to define donor LC as an A-type donor.
Cell lines were established using exogenous A- or B-type virus by infecting B lymphocytes
from an EBV seropositive donor Lc, with virus recovered from two A-type cell lines, IARC-
BL74 (8) and IARC-BL36, (4) and two B-type cell lines, Ag876 (3) and L4 (4) . Southern
and Western analyses were used to confirm the presence of A- or B-type virus in the respec-
tive LC transformants (designated LC/BL74, LC/BL36, LC/Ag876, and LC/L4) as previ-
ously described (6) .
CTL Activation and 5/Cr-release Assay.
￿
Lymphocytes from donor LC (HLA Al, B8, B18)
were cocultivated with the irradiated autologous A-type LCL, LC/BL74 for 3 d and the acti-
vatedT cells were cloned in agar and expanded in the presence ofIL-2 and specific stimulating
cells (2) . T cell clones were screened in the standard 5'Cr release assay (E/T ratio of 10:1)
against a panel of cell lines including autologous and allogeneic A- and B-type LCLs .
Peptide Selection.
￿
To identify the CTL epitope expressed on the A-type transformants but
not on the autologous B-type transformants, a series ofpeptides (20-25 amino acids) deduced
from the known sequences of the A-type EBNAs 2, 3, 4, 5, and 6 proteins were synthesized
(9) and screened on the autologous B-type transformant LC/Ag876 . Peptides selected were
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primarily those in which the A- and B-type sequences had diverged and/or corresponded
to the predicted algorithms ofDe Lisi and Berzofsky (10) and Rothbard and Taylor (11) .
Screening Peptides as Pbtential CTL Epitopes.
￿
EBNA peptides synthesized were distributed
in duplicate into U-well microtiter wells in RPMI 1640 (200 Etg/ml, 20 Al/well) and frozen
at -70°C until required . "Cr-labeled PHA blasts or LCLs from autologous and allogeneic
donors were added to each well (2 x 105/ml, 50 P,l/well) and incubated at 37°C. After I h,
130 pl of cells from the CTL cloned lines from donorLC were added to the reaction mixture
(final E/T ratio of 10 to 1) and the assay was conducted as described above .
Results and Discussion
Eight EBVspecific T cell clones were isolated (all CD8+ , class I restricted) with
a pattern of specificity similar to that previously described, i.e ., EBVspecificT cell
clones that recognized the autologous A-type transformants but failed to recognize
the autologous 13-type transformants (referred to as A-type-specificT cell clones).
Clone 13 was used as a typical representative of these clones and the data presented
refer to results obtained with this clone (Fig. 1) .
Peptides were screened as possible T cell epitopes by assaying their ability to re-
store recognition of the B-type transformant by specific CTLs . Of the 76 peptides
screened only 1 (peptide 68) restored the level of lysis of the B-type transformant
to that of the A-type transformant (Fig . 2) . The sequence of this peptide derived
from theEBNA 3 protein (BERF1 and BLRF3 reading frames) is TETAQAWNA-
GFLRGRAYGIDLLRTE (residues 329-353) . This result has been confirmed in 12
consecutive experiments using three separate syntheses of peptide 68. Titration of
the activity of this peptide using the B-type transformants from LC revealed that
it was 50% active at 2 ag/ml . It should be noted that we have excluded toxicity of
peptide 68 as the reason for the lysisdemonstrated . Thelevel of toxicity of this pep-
tide towards the B-type transformant was <5% when used at five times that in Fig . 2 .
The restrictingMHC determinant recognized by clone 13 was definedusing LCLs
andPHA blasts (grown for 3-5 wk in IL-2) from autologous and allogeneic donors
in the presence and absence of peptide 68 (Fig. 3) . The results showed thatT cell
recognition ofthepeptide was throughHLA B8 and that lysis was blocked by mAb
to class I determinants . Recent experiments have shown that 8/8 EBVspecific A-type-
specific clones established from this donor recognized this amino acid sequence ex-
FIGURE 1 .
￿
Percentage specific lysis by
clone 13 of autologous A-type LCLs
LCBL36 and LC/BL74 (AI andA2)
and B-type LCLs LC/Ag876 and
LC/L4 (BI and B2) and allogeneic
LCLs from HLA-unrelated donors(C,
D, and E) and K562 (F) . The LCLs
C andD were transformed with virus
from IARC-BL36and the LCLEwas
transformedwith virus from the B-type
transformant Ag876 . mAbs specific for
the monomorphic determinants on
class I (1,620, N) or class 11 (1,622, 19)
HLAantigens (provided by 1 .McKen-
zie, Melbourne) were tested for their
ability to block autologous killing by
clone 13 .Peptide derivation
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FIGURE 2.
￿
Percentage specific lysis of the B-type
LCL, LC/Ag876 byclone 13 afterpreincubationwith
peptides from EBNAs 2 (39 peptides tested), 3 (14
tested), 4 (11 tested), 5 (4 tested), and 6 (8 tested).
FIGURE 3.
￿
Lysisby clone 13 ofthe
autologous A-type target LCBL74,
the autologous B-type target LC/
Ag876, autologous (auto) PHA
blasts, and HLA-related and -un-
relatedallogeneic LCLs and PHA
blasts in thepresence (N)and ab-
sence(p)ofpeptide 68. In thisex-
periment, target cells were incu-
bated with peptide 68 (20 Irg/ml,
0.5 ml) for 30 min before SICr
labeling.
clusively (ofthese tested), suggesting that this EBV CTL epitope was dominant for
this donor.
We have recently shown that similar clones from 2/2 other B8 donors also recog-
nize peptide 68 suggesting that this peptide frequently associates with this allele.
In contrast, EBVspecific T cell colonies from 12 non-B8 donors failed to recognize
peptide 68 (data not shown).
To further define this epitope, three overlapping 15 mers from peptide 68, 68a
(residues 329-343), 68b (residues 334-348), and 68c (residues 339-353) were pre-
pared and tested for their ability to restore the level oflysis ofthe B-type transfor-
mant to that of the A-type transformant. The results demonstrated that all ofthe
activity was included in 68b and 68c (Fig. 4).
TheTcell epitope described in this communication is the first report ofan EBV
encoded sequence capable ofacting as a target forEBVspecific CTL lysis. An ear-
lier report (12) described a sequence from the EBV latent membrane protein that
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activated aCTL response butwas apparently incapableofacting as atarget forCTL
recognition. The present data are strongly supported by recent results using clone
13 in whichithas been demonstrated that LC/Ag876 (B-typetransformant)was ren-
dered susceptible to lysis by clone 13 after infection with vaccinia virus containing
the recombinant EBNA 3 gene, but was not susceptible to lysis when similar con-
structs containing EBNA 2, 4, 5, or 6 were used (Murray, R. J., et al., manuscript
submitted for publication).
The present study has important implications in the overall biologyofEBV, par-
ticularly in regard to the ability ofEBVspecific T cells to recognize and kill EBV
associated tumors. Burkitt's lymphoma (BL) cells that express only EBNA 1 have
already been shown to be refractory to EBVspecific Tcell recognition because of
downregulation ofboth class 1 antigens (13)and adhesionmolecules(14). Thedemon-
stration that a relevant CTL epitope is included in a protein that is not expressed
in BL provides another mechanism ofevading T cell recognition. It will be impor-
tant in the future to determine whether EBNA 1 includes any EBV CTL epitopes.
Summary
Epstein-Barr virus (EBV)-specificCTL clones were isolated that recognized A-type
EBV transformants but not B-type transformants. These A-type-specificCTLclones
(HLA B8 restricted) were used to screen peptides derived from the EBV nuclear
antigens(EBNAs) 2, 3, 4, and6 as potentialCTL epitopes. Ofthe76peptidesscreened,
one sequence from EBNA 3 (residues 329-353) was recognized by A-type-specific
CTL clones after absorption onto target cells (either autologous B-type transfor-
mants or PHA blasts). This report is the first description ofan EBV target epitope
recognized by specific CTL clones.
Receivedfor publication 2 October 1989.
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686, and68c(15mers). mAbs specific
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HLA antigens were tested for their
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